• 2019 Full Year Results: Continued growth from in-house innovation; Revenue doubled in last five years

    September 2019

    Long-term plan announced, incorporating investment to achieve revenue of £450-500m by FY24

    Cambridge, UK: Abcam (AIM: ABC, “Abcam” or “The Group”), a global leader in the supply of life science research tools, today announces its preliminary results for the 12 months ended 30 June 2019.


    • Total revenue up 11.4% on a reported basis and 9.2% on a constant exchange rate (CER) basis
    • Gross margin up 60 basis points to 70.5%, benefiting from an increasing mix of in-house products
    • EBITDA margin of 32.4% (2017/18: 35.0%), with Adjusted EBITDA margin of 35.6% (2017/18: 37.9%), reflect planned strategic investments in the business
    • Operating profit margin of 21.6% (2017/18: 29.5%), after a £12.8m non-cash impairment charge relating to historic Enterprise Resource Planning (ERP) development costs. Adjusted operating profit margin of 32.2% (2017/18: 34.9%)
    • Reported PBT declined to £56.4m (2017/18: £69.1m). Adjusted PBT grew 2.8% to £83.9m
    • Reported diluted EPS was 21.8p whilst adjusted diluted EPS grew 0.6% to 32.6p
    • Net cash inflow from operating activities of £70.2m (2017/18: £63.3m)
    • Proposed final dividend of 8.58p (2017/18: 8.58p), taking the proposed total annual dividend to 12.13 pence per share, an increase of 1.1%


    • All product categories growing above underlying market rates and all strategic performance targets achieved:
      – Recombinant antibody revenue growth (CER) of +22.4% (target 20%+)
      – Immunoassay product revenue growth (CER) of +21.9% (target 20%+)
      – 12-month rolling transactional Net Promotor Score (tNPS) of 59%3 (target 57-67%)
    • Continued in-house innovation, with in-house product revenue growth of 13.6% (CER) and the introduction of the Group’s 18,000th recombinant antibody
    • Further enhancements made to product quality through knockout validation, recombinant antibodies, and other initiatives to improve quality
    • Ongoing development of our addressable market in Custom Products and Licensing (CP&L), with 57 new agreements entered into with biopharmaceutical and diagnostic partners and over 160 custom projects completed during the year
    • Implemented the financial and non-stock procurement modules of our global ERP system
    • Successfully relocated to our new global headquarters in Cambridge, UK

    Alan Hirzel, Abcam’s Chief Executive Officer, said:

    “Our dedication to customer needs, team performance and our long-term investment perspective has helped Abcam to achieve sustained growth and expand its reach and influence over the last five years. Today, we are in a better position than ever before to pursue opportunities to continue to invest in, build and grow a successful global company.”

    “We are reassured that there is more to do and excited about the future prospects for our industry and our business. We are eager to enter a new phase of growth in the coming five years to extend further our impact on research discovery and clinical applications to improve patient lives”


    Read the full release

    About Abcam

    Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

    Read more +

    Abcam Products

    As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

    Read more +

    Investor Information

    Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

    Read more +

    Abcam News

    We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

    Read more +